Publication | Closed Access

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Disease Progression/intoleranceOncologyPancreatic CancerGastrointestinal OncologyMedicinePharmacotherapyJanus 1Cancer TreatmentPharmacologyRadiation OncologyAdvanced/metastatic Pancreatic Cancer